logo
logo
AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + proprietary hiring database
✓Executive contact details included
INDUSTRY FIRST

Incyte Appoints Bill Meury As President and Chief Executive Officer

Jun 26, 2025•about 2 months ago

Position

President

Company

Incyte

Bill Meury
WilmingtonBiopharmaTherapeuticsPharmaceuticalBiotechnology

Description

Incyte has appointed Bill Meury as its new President and Chief Executive Officer, effective immediately, succeeding Hervé Hoppenot. Meury brings extensive experience from previous roles in the pharmaceutical industry and will lead the company's growth in innovative treatments.

Company Information

Company

Incyte

Location

Wilmington, Delaware, United States

About

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity.

Company News

(10 articles)
Thu, 10 Jul 2025 07:00:00 GMT

Incyte to Report Second Quarter Financial Results - Business Wire

Fri, 06 Jun 2025 07:00:00 GMT

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Wed, 16 Oct 2024 07:00:00 GMT

Incyte Announces Health Canada Approval of OPZELURA® (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) and Nonsegmental Vitiligo - PR Newswire Canada

Thu, 20 Feb 2025 08:00:00 GMT

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Business Wire

Wed, 18 Jun 2025 07:00:00 GMT

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma - Business Wire

Sun, 15 Jun 2025 07:00:00 GMT

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Business Wire

Wed, 08 Jan 2025 08:00:00 GMT

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mon, 17 Mar 2025 07:00:00 GMT

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa - Business Wire

Thu, 26 Jun 2025 07:00:00 GMT

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire - Business Wire

Wed, 02 Jul 2025 07:00:00 GMT

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

FundzWatch™ Score

71
Medium Activity

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months